| |
Approaching early development strategically is critical to the later success of a drug candidate. Discover the current challenges and considerations for biotechs to maximize drug development outcomes. +(2)+(2).png)
|
|
Today’s Big NewsJan 14, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. 
|
|
| By Angus Liu,Fraiser Kansteiner,Kevin Dunleavy,Zoey Becker,Eric Sagonowsky As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli Lilly and more. |
|
|
|
By Angus Liu Roche has about $10 billion in M&A firepower it can deploy every year, but it’s “not just going to spend money,” the company’s pharma CEO Teresa Graham said at the J.P. Morgan Healthcare Conference. |
By James Waldron The release name-checked UB-VV400, an off-the-shelf, multidomain fusion protein surface-engineered lentiviral vector designed to generate CD22-directed CAR-T cells within a patient’s body. |
By Conor Hale The blood sugar tracking company offered a preliminary look at its annual and fourth-quarter earnings report at the J.P. Morgan Healthcare Conference in San Francisco. |
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
By Eric Sagonowsky Each year at the J.P. Morgan Healthcare Conference, pharma CEOs are tasked with assuring and convincing investors that they’ve positioned their companies to overcome expected challenges. Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on. |
By Fraiser Kansteiner Less than two months after scoring what analysts deemed a ‘best-case’ FDA approval for its cardiomyopathy drug Attruby, California’s BridgeBio is stepping into the spotlight of the J.P. Morgan Healthcare Conference to tout just how quickly its potential blockbuster is catching on. |
By Nick Paul Taylor Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease trial, teeing the biotech up to run a confirmatory study of its ex-Astellas asset. But a cross-trial comparison suggests Amgen’s blockbuster may have the advantage on the efficacy front. |
By Kevin Dunleavy Regeneron had little explanation for a sequential decline in sales of Eylea HD from $392 million in the third quarter to $305 million in the fourth quarter. |
By James Waldron With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets. |
By Conor Hale SAN FRANCISCO—The CE mark allows the company to begin rolling out the treatment immediately, essentially as a software update, to current patients who have already received its Percept neurostimulator implants equipped with BrainSense technology. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into 2024's batch of new FDA drug approvals, highlighting some potential blockbusters and shifts from previous years' lists. |
|
|---|
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
.+(1).png)
